달포프리스틴+퀴누프리스틴 C화학적 특성, 용도, 생산
Clinical Use
A drug combination of the streptogramins, quinupristin and dalfopristin was approved for IV use in the
treatment of infections caused by vancomycin-resistant Enterococcus faeci um bacteremia as well as
skin/skin structure infections caused by MRSA and methicillin-sensitive Streptococcus pyogenes. Certain
strains of E. faecium are resistant to essentially all
other antibiotics, including vancomycin. The streptogramin type A compound dalfopristin binds to the 50S
ribosomal subparticle, resulting in a conformational change in the substrate. It appears that dalfopristin
binding creates a high-affinity binding site for quinupristin, accounting for the synergy.
달포프리스틴+퀴누프리스틴 준비 용품 및 원자재
원자재
준비 용품